Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
Soumya Poddar(University of California, Los Angeles), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Darawan Rinchai(Rockefeller University), Mike Mattie, Caron A. Jacobson(Dana-Farber Cancer Institute), Gayatri Tiwari, Madison Davis(Gilead Sciences (Australia)), Justin A. Budka(Gilead Sciences (United Kingdom)), Simone Filosto(Gilead Sciences (United States)), Shruti Salunkhe(Illinois College), Davide Bedognetti(Sidra Medical and Research Center), Jiali Yan(Shanghai Jiao Tong University), Wangshu Zhang, Sara Beygi(Gilead Sciences (Australia)), Harry Miao(Takeda (United States)), Weixin Peng(Gilead Sciences (Australia)), Qinghua Song(Biostatistical Consulting (United States)), R. Shen(Gilead Sciences (Australia))
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k